Israeli biopharmaceutical company UroGen Pharma Ltd. tapped Stephen Mullennix to replace Gary Titus as CFO on an interim basis.
Mullennix, who is the COO of the company, has actively led or participated in more than $3 billion worth of M&A, equity and debt financing transactions, UroGen said in a statement.
Titus will remain as a consultant during the transition.
"Gary played an important role in the early stages of building UroGen and in particular the success of both our initial public offering and recent follow on offering ... We now prepare for the next phase of our growth with the potential approval and commercialization of our first product," UroGen CEO Ron Bentsur said in a statement.
UroGen is working to commercialize its lead product candidates UGN-101 and UGN-102 to potentially remove tumors by nonsurgical means.
